Q4 2024 Pharming Group NV Earnings Call Transcript
Key Points
- Pharming Group (PHGUF) reported a 21% increase in full-year 2024 revenues, reaching $297 million, surpassing their guidance range.
- RUCONEST sales grew by 11% to $252 million, driven by a 24% increase in new patient enrollments and an 11% expansion of the prescriber base.
- Joenja revenue increased by 147% to $45 million, with significant growth expected from new patient enrollments and geographic expansion.
- The acquisition of Abliva is seen as a strategic move to enhance Pharming's pipeline, particularly in the area of primary mitochondrial diseases.
- Pharming Group (PHGUF) maintained positive operating cash flow and operating profits for the last two quarters of 2024, indicating strong financial health.
- Gross profit growth was lower than revenue growth due to a one-off inventory impairment related to RUCONEST production issues.
- Operating expenses increased by 10% due to investments in Joenja, which may impact profitability if not managed carefully.
- The company faces potential challenges from new competition in the HAE market, which could impact RUCONEST's market share.
- There are concerns about potential US tariffs affecting drug pricing and supply chain, which could impact Pharming's operations.
- The integration of Abliva and associated costs, estimated at $30 million for 2025, could strain resources if not managed effectively.
Thank you very much. Hello, everyone, and welcome to the Farming Full year and Q4 2024 financial results call. I'm Fabrice Chouraqui, CEO of Pharming , and I'll be joined on this call today by Steven Toor, our Chief Commercial Officer; Anurag Relan, our Chief Medical Officer; and Jeroen Wakkerman, our Chief Financial Officer.
We will be making forward-looking statements in this call that are based upon our current insights and plans. As you know, this may differ from future results.
First of all, let me say that I'm really excited to be joining Pharming, and it's an honor to succeed Sijmen de Vries. I'm passionate about progressing medical sciences and bringing innovation to patients. And naturally, I feel deeply connected with Pharming's mission to serve the unserved rare disease patients. Over the past 25 years, I've developed an experience across the business spectrum from pre-clinical research and clinical development to commercial leadership, business development, and capital formation.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
